Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Finalizing preclinical package to initiate clinical studies in 2022
Preclinical Proof of Concept in cancer models including combination with checkpoint inhibitors
Seeking funding by life science investors and partnerships in oncology & infectious diseases
News & Events
Immunetune's development of a vaccine against SARS-CoV-2 has been published as part of a consortium in Nature Communications in July 2022. In this specific publication, named 'A third vaccination with a single T cell epitope confers protection in a murine model of...
Accelerating Cancer Immunotherapy Research (ACIR) has featured Immunetune's presentation during the Cancer Immunotherapy (CIMT) Annual Meeting 2022 held May 10-12 in Mainz, Germany. At CIMT, our CSO Jeroen van Bergen presented new preclinical results on our neoantigen...
Immunetune and Daicel Initiate Research Collaboration on Vaccine Injection Device LEIDEN, the Netherlands; OSAKA, Japan; April 22, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases,...